COMP <GO>
DFTX vs MRK // ALTMAN Z-SCORE & DEBT/EQUITY
Definium Therapeutics Inc. (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: DFTX 3
— MRK 11
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: DFTX
LAST: $36.33 (-4.29%) • MKT CAP: $5.10B
balance-sheet
26.00
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
balance-sheet
5.19
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DFTX VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | DFTX | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 74.80% | -33.80 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -32.20% | 20.70% | -52.90 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.84% | 3.42% | -7.26 | MRK | /fcf-yield <GO> |
| Operating Margin | -11.60% | 34.30% | -45.90 | MRK | /operating-margins <GO> |
| Net Profit Margin | -12.90% | 28.10% | -41.00 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 5.50% | 1.30% | +4.20 | DFTX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 26.00 | 5.19 | +20.81 | DFTX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 6.60% | +0.60 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.4 | 56.9 | -7.47 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 0.92 | +0.16 | DFTX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 33.0x | 18.4x | +14.60 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.10B | $361.02B | -$355.92B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | DFTX REV | MRK REV | DFTX GROSS % | MRK GROSS % | DFTX FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $65.01B | — | 74.8% | -$131.6M | $12.36B |
| FY 2024 | $0 | $64.17B | — | 76.3% | -$79.1M | $18.10B |
| FY 2023 | $0 | $60.12B | — | 44.0% | -$64.4M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DFTX // BETA 1.08
MRK // BETA 0.92